136 related articles for article (PubMed ID: 37370819)
1. pCR and 2-Year Disease-Free Survival: A Combination of the Two Endpoints as a New Classification for Locally Advanced Rectal Cancer Patients-An Updated Pooled Analysis of Eleven International Randomized Trials.
Gambacorta MA; Chiloiro G; Masciocchi C; Mariani S; Romano A; Gonnelli A; Gerard JP; Ngan S; Rödel C; Bujko K; Glynne-Jones R; van Soest J; Dekker A; Damiani A; Valentini V
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370819
[TBL] [Abstract][Full Text] [Related]
2. Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer.
Valentini V; van Stiphout RG; Lammering G; Gambacorta MA; Barba MC; Bebenek M; Bonnetain F; Bosset JF; Bujko K; Cionini L; Gerard JP; Rödel C; Sainato A; Sauer R; Minsky BD; Collette L; Lambin P
Radiother Oncol; 2015 Mar; 114(3):302-9. PubMed ID: 25716096
[TBL] [Abstract][Full Text] [Related]
3. A Predictive Model of 2yDFS During MR-Guided RT Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients.
Chiloiro G; Boldrini L; Preziosi F; Cusumano D; Yadav P; Romano A; Placidi L; Lenkowicz J; Dinapoli N; Bassetti MF; Gambacorta MA; Valentini V
Front Oncol; 2022; 12():831712. PubMed ID: 35280799
[TBL] [Abstract][Full Text] [Related]
4. Delta Radiomic Analysis of Mesorectum to Predict Treatment Response and Prognosis in Locally Advanced Rectal Cancer.
Chiloiro G; Cusumano D; Romano A; Boldrini L; Nicolì G; Votta C; Tran HE; Barbaro B; Carano D; Valentini V; Gambacorta MA
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370692
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Combined Detection of RUNX3 and EZH2 in Evaluating Efficacy of Neoadjuvant Therapy and Prognostic Value of Middle and Low Locally Advanced Rectal Cancer.
Wang L; Wu X; Xu W; Gao L; Wang X; Li T
Front Oncol; 2022; 12():713335. PubMed ID: 35280723
[TBL] [Abstract][Full Text] [Related]
7. Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis.
Liu S; Jiang T; Xiao L; Yang S; Liu Q; Gao Y; Chen G; Xiao W
Oncologist; 2021 Sep; 26(9):e1555-e1566. PubMed ID: 33987952
[TBL] [Abstract][Full Text] [Related]
8. Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials.
Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
J Gastrointest Oncol; 2017 Feb; 8(1):39-48. PubMed ID: 28280607
[TBL] [Abstract][Full Text] [Related]
9. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.
Dudani S; Marginean H; Tang PA; Monzon JG; Raissouni S; Asmis TR; Goodwin RA; Gotfrit J; Cheung WY; Vickers MM
BMC Cancer; 2019 Jul; 19(1):664. PubMed ID: 31277604
[TBL] [Abstract][Full Text] [Related]
11. Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH).
Wang Y; Shen L; Wan J; Zhang H; Wu R; Wang J; Wang Y; Xu Y; Cai S; Zhang Z; Xia F
BMC Cancer; 2022 Mar; 22(1):274. PubMed ID: 35291966
[TBL] [Abstract][Full Text] [Related]
12. College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.
Chen HY; Feng LL; Li M; Ju HQ; Ding Y; Lan M; Song SM; Han WD; Yu L; Wei MB; Pang XL; He F; Liu S; Zheng J; Ma Y; Lin CY; Lan P; Huang MJ; Zou YF; Yang ZL; Wang T; Lang JY; Orangio GR; Poylin V; Ajani JA; Wang WH; Wan XB
Oncologist; 2021 May; 26(5):e780-e793. PubMed ID: 33543577
[TBL] [Abstract][Full Text] [Related]
13. Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer.
Ren DL; Li J; Yu HC; Peng SY; Lin WD; Wang XL; Ghoorun RA; Luo YX
World J Gastroenterol; 2019 Jan; 25(1):118-137. PubMed ID: 30643363
[TBL] [Abstract][Full Text] [Related]
14. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].
Wang YQ; Shen LJ; Wan JF; Zhang H; Wang Y; Wu X; Wang JW; Wang RJ; Sun YQ; Tong T; Huang D; Wang L; Sheng WQ; Zhang X; Cai GX; Xu Y; Cai SJ; Zhang Z; Xia F
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):448-458. PubMed ID: 37217353
[No Abstract] [Full Text] [Related]
15. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
16. Prognostic significance of early complete response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy: Multicentric study of Turkish Society for Radiation Oncology Group (TROD).
Kılıç D; Sert F; Görken İB; Arıcan Alıcıkuş Z; Aktürk N; Kaytan Sağlam E; Kizir A; Özkök S; Yılmaz HT; Göçen F; Yalman D
Turk J Gastroenterol; 2020 May; 31(5):368-377. PubMed ID: 32519956
[TBL] [Abstract][Full Text] [Related]
17. Prognostic risk factors and survival models for T3 locally advanced rectal cancer: what can we learn from the baseline MRI?
Zhao Q; Wan L; Zou S; Zhang C; E T; Yang Y; Ye F; Zhao X; Ouyang H; Zhang H
Eur Radiol; 2021 Jul; 31(7):4739-4750. PubMed ID: 34003351
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic value of inflammatory markers in locally advanced rectal cancer (PILLAR) - A multicentric analysis by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Study Group.
Chiloiro G; Romano A; Mariani S; Macchia G; Giannarelli D; Caravatta L; Franco P; Boldrini L; Arcelli A; Bacigalupo A; Belgioia L; Fontana A; Meldolesi E; Montesi G; Niespolo RM; Palazzari E; Piva C; Valentini V; Gambacorta MA
Clin Transl Radiat Oncol; 2023 Mar; 39():100579. PubMed ID: 36935859
[TBL] [Abstract][Full Text] [Related]
19. The high pCR rate of sandwich neoadjuvant treatment in locally advanced rectal cancer may translate into a better long-term survival benefit: 5-year outcome of a Phase II clinical trial.
Hu YH; Wei JW; Chang H; Xiao WW; Lin JZ; Cai MY; Cai PQ; Kong LH; Chen G; Pan ZZ; Zeng ZF; Ding PR; Gao YH
Cancer Manag Res; 2018; 10():4363-4369. PubMed ID: 30349369
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of neoadjuvant rectal score-based signature nomograms to predict overall survival and disease-free survival in locally advanced rectal cancer: a retrospective, double center, cohort study.
Wang G; Tang Z; Ye J; Tang H; Yao K; Zeng Q; Yang Y; Fu M; Luo L; Shen Q; Fang X; Ling B; Fang Y; Guo Y; Huang Y
Int J Clin Oncol; 2023 Feb; 28(2):268-279. PubMed ID: 36534264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
